Autonomix releases testimonial of patient in trial of pancreatic cancer pain

Autonomix (AMIX) Medical announced the release of a new video testimonial from a patient participating in the initial phase of its first-in-human proof-of-concept trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant nerves and mitigate pain in patients with severe pancreatic cancer pain. “We are deeply grateful to the patients who have shared their experiences with us. Testimonials like this provide meaningful insight into the real-world impact our technology can have, particularly in improving quality of life and reducing dependence on pain medication,” said Brad Hauser, Chief Executive Officer of Autonomix. “Patients with late-stage pancreatic cancer face severe, often unrelenting pain. Data emerging from our ongoing study reinforce the significant burden this pain places on quality of life and point to a clear, unmet need for innovative interventional pain management solutions.”